BNCT and Bevacizumab: A Promising Duo in Recurrent Glioma Treatment?
"Exploring a pilot study on combining boron neutron capture therapy (BNCT) with bevacizumab for recurrent malignant gliomas."
Recurrent malignant gliomas (RMGs) pose a significant challenge in oncology, with limited effective treatment options available. Boron neutron capture therapy (BNCT), a targeted radiation therapy, has shown promise, but can lead to brain radiation necrosis (BRN) as a side effect. This necrosis can cause severe neurological complications, diminishing the benefits of the treatment.
To combat BRN, researchers have explored the use of bevacizumab (BV), an anti-VEGF antibody known for its ability to reduce edema and inflammation. A recent pilot study investigated the combination of BNCT with early, successive BV treatments to mitigate BRN and improve outcomes for RMG patients.
This article delves into the findings of this pilot study, examining the feasibility, efficacy, and BRN control achieved by combining BNCT and bevacizumab. We will explore the potential of this combination therapy to extend survival and improve the quality of life for individuals battling recurrent malignant gliomas.
Current Glioma Treatment and Its Limits
Standard glioblastoma treatment combines surgery, radiotherapy, and chemotherapy, but reported average survival remains 12.1 to 14.6 months. Intensity-modulated radiation therapy is widely used because it can increase the irradiation dose while reducing damage to normal brain tissue. Treatment remains difficult because glioblastoma can evade immune responses, repopulate through stem cells, and limit drug penetration across the blood-brain barrier. Clinical care and outcomes also differ substantially between pediatric and adult glioma patients.
How Does Combining BNCT and Bevacizumab Work?
The pilot study involved seven patients with recurrent malignant gliomas who underwent BNCT followed by a course of bevacizumab treatments. BNCT works by selectively targeting tumor cells with a boron compound and then irradiating them with neutrons, leading to cell death. Bevacizumab, administered shortly after BNCT, aims to counteract the development of BRN by inhibiting VEGF, a key factor in edema formation and inflammation.
- Feasibility: Evaluating the occurrence of adverse events associated with the combined treatment.
- Efficacy: Measuring overall survival (OS) and progression-free survival (PFS) to determine the treatment's impact on disease progression.
- BRN Control: Assessing the ability of the combination therapy to prevent or manage brain radiation necrosis.
Emerging BNCT-Bevacizumab Research
Recent BNCT clinical-trial reviews identify cohorts designed by Miyatake and colleagues to study BNCT combined with early bevacizumab treatment for recurrent malignant gliomas. A multicenter, dose-escalation phase 1 trial separately evaluated BNCT in recurrent high-grade gliomas, with bevacizumab prohibited so that BNCT's safety profile could be assessed distinctly. That trial highlighted symptomatic pseudoprogression as a central clinical concern affecting the Safety Committee's recommended RP2D. Reviews also describe BNCT as a novel strategy for recurrent glioblastoma, where chemotherapy has limited survival benefit and conventional radiotherapy remains controversial.
Why the Combination Remains Unproven
The pilot study of BNCT with early successive bevacizumab treatments notes that bevacizumab did not prolong overall survival in two large phase 3 trials for newly diagnosed glioblastoma. In recurrent glioblastoma, the phase 3 EORTC 26101 trial likewise found no overall-survival contribution from bevacizumab, although a phase 2 trial produced promising results. More broadly, glioblastoma remains mostly incurable despite surgery, radiation therapy, and temozolomide because of its invasive growth. Treatment failure is also linked to tumor heterogeneity, cancer stem cells, and an immunosuppressive tumor microenvironment.
The Future of RMG Treatment: A Glimmer of Hope
This pilot study suggests that combining BNCT with early bevacizumab treatments can effectively prevent or control BRN, prolong overall survival, and maintain an acceptable incidence of adverse events in patients with recurrent malignant gliomas. These findings offer a promising avenue for improving treatment outcomes in this challenging patient population.
A Cautious Evidence-Based Position
There is broad consensus on treating primary adult high-grade gliomas, but management of recurrent glioma varies because research is limited and proven survival benefits are lacking. Malignant gliomas are particularly difficult to treat because of infiltrative growth, rapid progression, poor prognosis, and the blood-brain barrier. Many antitumor drugs do not adequately reach gliomas, while temozolomide is identified as a first-line agent that can cross the blood-brain barrier. Recent reviews continue to describe blood-brain-barrier limitations as a major challenge in high-grade glioma therapy.
Beyond Minimal Clinical Benefit
The standard of care for glioblastoma offers minimal clinical benefit, and most patients experience tumor recurrence. Glioblastoma Therapy: Past, Present and Future describes glioblastoma as a grade IV astrocytoma and emphasizes the importance of genetic and molecular alterations in the World Health Organization's 2021 diagnostic criteria. Future progress therefore depends on developing treatments that account for the disease's biological and molecular complexity. Immunotherapy remains an area of active consideration, although current challenges continue to limit its impact.
Real-World Outcomes and Patient Diversity
Despite new treatment options, prognosis for patients with glioblastoma remains poor, and real-world reports continue to examine the clinical course of patients receiving personalized neoantigen treatment. Real-world evidence is also being used to evaluate clinically actionable targets in glioma diagnosis and treatment through next-generation sequencing. A 2025 case report notes that glioblastoma affects about three people per 100,000 per year and reports a three-year survival rate of about 10%, falling to about 5% among patients older than 65. These figures reinforce why treatment decisions must account for patient age, molecular features, and outcomes observed beyond controlled trials.
The study authors emphasize the need for further research to validate these preliminary results and optimize the treatment protocol. A prospective clinical trial is currently underway to investigate BNCT and simultaneous BV treatments for poor prognosis patients with recurrent malignant glioma, potentially solidifying this combination therapy as a new standard of care.
While the results are promising, it's important to note the small sample size of the study. Larger, multi-center trials are needed to confirm these findings and determine the optimal dosage and timing of bevacizumab in conjunction with BNCT. The future of RMG treatment may very well depend on innovative combinations like this, offering renewed hope for patients and their families.